CryoLife Stock Forecast, Price & News

+0.26 (+0.89 %)
(As of 06/15/2021 03:51 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume3,437 shs
Average Volume175,751 shs
Market Capitalization$1.15 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive CRY News and Ratings via Email

Sign-up to receive the latest news and ratings for CryoLife and its competitors with MarketBeat's FREE daily newsletter.

CryoLife logo

About CryoLife

CryoLife, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. It offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X prosthetic aortic and mitral heart valve, and On-X ascending aortic prosthesis; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita OPEN PLUS and E-vita OPEN NEO, a hybrid stent graft system. The company also provides E-xtra DESIGN ENGINEERING products for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, it offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; and cardiac laser therapy products, such as SolarGen 2100s Console and SoloGrip III disposable handpieces. Further, the company sells CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as offers pyrolytic carbon coating services to other medical device manufacturers. The company serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. CryoLife, Inc. was founded in 1984 and is headquartered in Kennesaw, Georgia.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.32 out of 5 stars

Medical Sector

843rd out of 2,100 stocks

Surgical & Medical Instruments Industry

80th out of 174 stocks

Analyst Opinion: 1.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

CryoLife (NYSE:CRY) Frequently Asked Questions

Is CryoLife a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CryoLife in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CryoLife stock.
View analyst ratings for CryoLife
or view top-rated stocks.

What stocks does MarketBeat like better than CryoLife?

Wall Street analysts have given CryoLife a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but CryoLife wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is CryoLife's next earnings date?

CryoLife is scheduled to release its next quarterly earnings announcement on Thursday, July 29th 2021.
View our earnings forecast for CryoLife

How were CryoLife's earnings last quarter?

CryoLife, Inc. (NYSE:CRY) announced its quarterly earnings results on Thursday, April, 29th. The medical equipment provider reported ($0.08) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.11) by $0.03. The medical equipment provider had revenue of $71.09 million for the quarter, compared to the consensus estimate of $61.70 million. CryoLife had a positive trailing twelve-month return on equity of 3.00% and a negative net margin of 5.10%.
View CryoLife's earnings history

How has CryoLife's stock price been impacted by COVID-19?

CryoLife's stock was trading at $23.87 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CRY stock has increased by 23.2% and is now trading at $29.40.
View which stocks have been most impacted by COVID-19

What price target have analysts set for CRY?

2 analysts have issued 12 month price objectives for CryoLife's stock. Their forecasts range from $25.00 to $38.00. On average, they anticipate CryoLife's share price to reach $31.50 in the next year. This suggests a possible upside of 7.1% from the stock's current price.
View analysts' price targets for CryoLife
or view top-rated stocks among Wall Street analysts.

Who are CryoLife's key executives?

CryoLife's management team includes the following people:
  • Mr. James Patrick Mackin, Chairman, Pres & CEO (Age 54, Pay $1.09M)
  • Mr. David Ashley Lee CPA, CPA, Exec. VP, COO & CFO (Age 56, Pay $579.08k)
  • Ms. Jean F. Holloway Esq., Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 64, Pay $476.26k)
  • Mr. John E. Davis, Sr. VP of Global Sales & Marketing (Age 56, Pay $436.39k)
  • Ms. Amy D. Horton CPA, CPA, VP & Chief Accounting Officer (Age 51)
  • Mr. Matthew A. Getz, VP of HR (Age 52)
  • Joshua Wells, Sr. Director of Bus. Devel.
  • Dr. Marshall S. Stanton, Sr. VP of Clinical Research & Chief Medical Officer
  • Karen K. Dabbs, Assistant Corp. Sec.

What is J. Patrick Mackin's approval rating as CryoLife's CEO?

53 employees have rated CryoLife CEO J. Patrick Mackin on Glassdoor.com. J. Patrick Mackin has an approval rating of 81% among CryoLife's employees.

Who are some of CryoLife's key competitors?

What other stocks do shareholders of CryoLife own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CryoLife investors own include Energy Transfer (ET), AT&T (T), NVIDIA (NVDA), Teva Pharmaceutical Industries (TEVA), Enterprise Products Partners (EPD), Gilead Sciences (GILD), Netflix (NFLX), Zoetis (ZTS), Ares Capital (ARCC) and Edwards Lifesciences (EW).

What is CryoLife's stock symbol?

CryoLife trades on the New York Stock Exchange (NYSE) under the ticker symbol "CRY."

Who are CryoLife's major shareholders?

CryoLife's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (17.82%), Wasatch Advisors Inc. (8.20%), Morgan Stanley (4.27%), GW&K Investment Management LLC (3.63%), Dimensional Fund Advisors LP (3.10%) and William Blair Investment Management LLC (2.44%). Company insiders that own CryoLife stock include Amy Horton, David Ashley Lee, Dennis B Maier, James P Mackin, Jean F Holloway, John E Davis, Ronald D Mccall and Scott B Capps.
View institutional ownership trends for CryoLife

Which institutional investors are selling CryoLife stock?

CRY stock was sold by a variety of institutional investors in the last quarter, including Ophir Asset Management Pty Ltd, Dimensional Fund Advisors LP, Royce & Associates LP, Russell Investments Group Ltd., Nuveen Asset Management LLC, D. E. Shaw & Co. Inc., Kennedy Capital Management Inc., and Northern Trust Corp. Company insiders that have sold CryoLife company stock in the last year include Amy Horton, David Ashley Lee, Dennis B Maier, Jean F Holloway, John E Davis, Ronald D Mccall, and Scott B Capps.
View insider buying and selling activity for CryoLife
or view top insider-selling stocks.

Which institutional investors are buying CryoLife stock?

CRY stock was acquired by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., BlackRock Inc., Morgan Stanley, Victory Capital Management Inc., Millennium Management LLC, William Blair Investment Management LLC, Geode Capital Management LLC, and UBS Group AG. Company insiders that have bought CryoLife stock in the last two years include James P Mackin, and John E Davis.
View insider buying and selling activity for CryoLife
or or view top insider-buying stocks.

How do I buy shares of CryoLife?

Shares of CRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CryoLife's stock price today?

One share of CRY stock can currently be purchased for approximately $29.40.

How much money does CryoLife make?

CryoLife has a market capitalization of $1.15 billion and generates $253.23 million in revenue each year. The medical equipment provider earns $-16,680,000.00 in net income (profit) each year or $0.25 on an earnings per share basis.

How many employees does CryoLife have?

CryoLife employs 1,200 workers across the globe.

What is CryoLife's official website?

The official website for CryoLife is www.cryolife.com.

Where are CryoLife's headquarters?

CryoLife is headquartered at 1655 Roberts Boulevard N.W, Kennesaw GA, 30144.

How can I contact CryoLife?

CryoLife's mailing address is 1655 Roberts Boulevard N.W, Kennesaw GA, 30144. The medical equipment provider can be reached via phone at 770-419-3355 or via email at [email protected]

This page was last updated on 6/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.